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Abstract
Background: Protein-Protein Interactions (PPIs) are key for many cellular processes. The characterization of PPI
interfaces and the prediction of putative ligand binding sites and hot spot residues are essential to design efficient
small-molecule modulators of PPI. Terphenyl and its derivatives are small organic molecules known to mimic one
face of protein-binding alpha-helical peptides. In this work we focus on several PPIs mediated by alpha-helical
peptides.
Method: We performed computational sequence- and structure-based analyses in order to evaluate several key
physicochemical and surface properties of proteins known to interact with alpha-helical peptides and/or terphenyl
and its derivatives.
Results: Sequence-based analysis revealed low sequence identity between some of the analyzed proteins binding
alpha-helical peptides. Structure-based analysis was performed to calculate the volume, the fractal dimension
roughness and the hydrophobicity of the binding regions. Besides the overall hydrophobic character of the binding
pockets, some specificities were detected. We showed that the hydrophobicity is not uniformly distributed
in different alpha-helix binding pockets that can help to identify key hydrophobic hot spots.
Conclusions: The presence of hydrophobic cavities at the protein surface with a more complex shape than the
entire protein surface seems to be an important property related to the ability of proteins to bind alpha-helical
peptides and low molecular weight mimetics. Characterization of similarities and specificities of PPI binding sites
can be helpful for further development of small molecules targeting alpha-helix binding proteins.
Background
Protein-Protein Interactions (PPIs) are key to many cellu-
lar processes. Abnormal PPIs contribute to many disease
states and as such, PPIs represent today a new class of
drug targets essentially unexploited for drug discovery.
Indeed, the size of the human interactome has been esti-
mated to be between 300,000 [1] and 650,000 interactions
[2]. In the last decade many studies have been performed
in order to target PPIs [3]. Several small-molecule inhibi-
tors of PPIs have been demonstrated therapeutic potential
[4-8]. However, efficient targeting of PPIs is still being
considered as an important challenge [3,9,10]. In contrast
to enzyme-substrate interactions, protein-protein recogni-
tion often occurs through flat surfaces or wide shallow
grooves. Recent structural analyses of PPI interfaces and
small molecules disrupting PPIs suggested that such li-
gands might mimic the structural characteristics of the
protein partner [6,11]. To facilitate the discovery of new
PPI small-molecule inhibitors, the characterization of PPI
interfaces [12,13] and the prediction of putative ligand
binding sites are essential. Physicochemical properties of
both ligand and protein are key to mediate the binding
[14], such as cavity sizes, shape complementarity, electro-
static potential and hydrophobicity [12,15].
The role of alpha-helical peptides in mediating many
PPIs is well demonstrated and development of small or-
ganic molecules mimicking such peptides becomes im-
portant [16]. Recent studies have been carried out on
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the whole Protein Data Bank (PDB) in order to establish
a druggability profile of alpha-helix mediated PPIs and
to predict which of them could bind a small molecule
[17]. More specifically, terphenyl and its derivates are
small organic molecules [18-26] mimicking one face of
an alpha-helical peptide, i.e. the side chains of three key
residues occupying positions i, i+3 and i+7 [25,26] or i,
i+4 and i+7 [20] of the bound helix. It has been sug-
gested that terphenyl compounds can serve as pharma-
cological probes because they are membrane permeable
[22]. Terphenyl 1 and 2, which mimic the calmodulin
binding face of smooth muscle myosin light chain kinase
(smMLCK), have been shown to inhibit the interactions
of calmodulin (CaM) with the enzyme 3'-5'-cyclic nu-
cleotide phosphodiesterase (PDE) and with the helical
peptide C20W of the plasma membrane calcium pumps
[18]. Following the similarity between the calmodulin
and human centrin 2 (HsCen2) alpha-helix binding sites,
we recently suggested that terphenyl 2 might also inhibit
the interaction between HsCen2 and a 17 residues pep-
tide of Xeroderma Pigmentosum Group C (XPC) protein
[27]. Terphenyl derivates mimicking the alpha-helical
structure of p53 N-terminal peptide inhibit the p53-
MDM2 [22] and the p53-HDM2 interactions [21]. These
molecules also mimic the alpha-helical region of Bak
BH3 domain, which binds BCL-X2, thus disrupting the
BCL-X2/Bak interaction [19,20,24].
In this work we performed a computational analysis in
order to evaluate several key physicochemical and surface
properties of proteins known to interact with alpha-
helical peptides or to bind terphenyl and its derivatives.
We calculated the binding pocket volumes and the fractal
dimensions of the surface cavities for the entire protein
and for the binding pockets. We identified several simila-
rities and specificities characterizing such protein binding
sites that can be helpful for future development of more
efficient small-molecule inhibitors targeting alpha-helix
binding proteins.
Methods
In this study we compared the sequence and surface prop-
erties of the investigated proteins. In order to analyze the
Table 1 Protein – alpha-helical peptide complexes




Interacting residues of the
bound alpha-helix
Chicken calmodulin in complex with smooth muscle myosin light chain kinase
(smMLCK)
2O5G* P62149 TRP5, THR8, VAL12
1.08 Å
Human calmodulin in complex with a mutant peptide of human DRP-1 kinase 1ZUZ P62158 TRP305, PHE309, VAL312
1.91 Å
Human calmodulin in complex with CAV1.1 IQ peptide 2VAY* P62158 THR526, ILE529, PHE533
1.94 Å
Human calmodulin in complex with CAV2.2 IQ peptide 3DVE P62158 MET854, VAL857, MET161
2.35 Å
E Coli calmodulin in complex with RS20 peptide of smMLCK 1QTX - TRP5, THR8, VAL12
1.65 Å
Rat calmodulin in complex with NMDA receptor NR1C1peptide 2HQW P62161 PHE880, THR884, LEU887
1.90 Å
Human centrin 2 in complex with the centrin binding region of XPC protein 2GGM P41208 TRP848, LEU851, LEU855
2.35 Å
C-terminal domain of human centrin 2 in complex with a repeat sequence of
human Sfi 1
2K2I P41208 LEU651, LEU655, TRP658
NMR
Scherffelia dubia centrin in complex with smMLCK peptide 3KF9 Q06827 TRP4, PHE8, VAL11
2.60 Å
Human BCL-XL in complex with BAK peptide 1BXL* Q07817 VAL574, LEU578, ILE581
NMR
Human E3 ubiquitin-protein ligase MDM2 in complex with p53 tumor
transactivation domain (fragment 17-125)
1YCR* Q00987 PHE19, TRP23, LEU26
2.60 Å
Rabbit cardiac troponin C in complex with a fragment (residues 1-47) of cardiac
troponin I
1A2X P02586 LEU17, MET21, ILE24
2.30 Å
*known to be disrupted by terphenyl or its derivatives.
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sequence similarities we performed sequence alignment
using the CLUSTALW software [28]. Interacting residues
at the protein-protein interface in terms of contact dis-
tances were found using the ContPro online freely avai-
lable tool [29]. We identified the protein residues
interacting with the three key residues of the alpha-helical
peptide (occupying positions i, i+3 and i+7 or i, i+4 and
i+7) those relative positions are mimicked by terphenyl
and its derivatives. The distance threshold was set to 5 Å
for the side chain atoms.
In order to evaluate the protein surface properties, the
bound peptide was removed for each complex. The surface
characteristics of the entire protein and those of the
peptide-binding cavity were analyzed. Using the ap-
proach of the fractal geometry we quantitatively de-
scribed the surface roughness for the entire protein and
for the binding cavity, expressed by global surface frac-
tal dimension (DS) and local surface fractal dimension
(DL), respectively. In order to calculate the surface frac-
tal dimension we used the method proposed by Lewis
and Rees [30] based on the scaling law between the sur-
face area (SA) and the radius of the rolling probe mol-
ecule (R) on the surface, i.e. SA is proportional to the
radius to the power 2-Ds:
SAeR2−DS ð1Þ
The surface fractal dimension was determined from
the slope of the double logarithmical plot of SA versus
R. The surface area of the protein was computed using
the on-line available software GETAREA [31]. Probe
radii of 1, 1.2, 1.4, 1.6, 1.8 and 2 Å were used. For the
Figure 1 Sequence alignment of alpha-helix binding proteins. The amino acid residues interacting with alpha-helical peptides are presented
in red.
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Table 2 Sequence identity (in %) between the considered proteins (the binding area/entire protein)








Human E3 ubiquitin-protein ligase
MDM2
Human centrin 2 54/50
Scherffelia dubia centrin 56/55 90/74
Human BCL-X2 5/7 5/5 5/8
Human E3 ubiquitin-protein ligase
MDM2
5/4 5/10 7/6 9/5
Rabbit cardiac troponin C 57/51 57/34 37/32 5/9 5/19
The binding area was defined here as all residues of the protein interacting with the helical peptide.
Figure 2 3D structures of the complexes formed by: (a) human centrin 2 and a 10 residue peptide of Xeroderma Pigmentosum group C
protein, code entry 2GGM. (b) chicken calmodulin and smooth muscle myosin light chain kinase (smMLCK), code entry 2O5G. (c) scherffelia dubia
centrin and smMLCK peptide, code entry 3KF9. (d) rabbit cardiac troponin C and a fragment of cardiac troponin I, code entry 1A2X. (e) human
BCL-XL and BAK peptide, code entry 1BXL. (f) human E3 ubiquitin-protein ligase MDM2 and p53 tumor transactivation domain, code entry 1YCR.
All proteins are shown as surface in atom color type (C and H-white, N – blue, O -red, S – yellow) and ligands are shown in magenta cartoon
with hydrophobic interacting residues given as sticks.
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proteins cavities, the same algorithm was employed
using the CASTp software [32]. Hydrophobicity and
local hydrophobic density for binding pockets were de-
termined using Fpocket [33]. Pocket volumes were com-
puted using CASTp [32].
Molecular docking of terphenyl 2 was performed into
the alpha-helical binding sites of calmodulin (code entry
2O5G) and troponin C (code entry 1A2X) using AutoDock
4.2 [34]. The input files preparation and docking analysis
were carried out using AutoDockTools. Grid maps were
centered in the alpha-helix binding site for both structures.
Grids sizes were 126 Å x 126 Å x 126 Å with a grid spa-
cing of 0.33 Å for calmodulin and 126 Å x 126 Å x 126 Å
with a grid spacing of 0.28 Å for troponin C. Ligand con-
formational searching was performed using Lamarckian
genetic algorithm and all ligand torsion angles were flex-
ible. The following docking parameters were used: 250
Lamarckian genetic algorithm runs, a population size of
250, a maximum of 2 500 000 energy evaluations and a
maximum of 27000 generations.




We analyze several proteins interacting with alpha-
helical peptides, some of them being known to bind also
terphenyl and/or its derivatives. To characterize and
compare their surface properties we examine the se-
quences and the three dimensional (3D) structures of
the complexes formed by the protein and the bound
peptide. The 3D structures are retrieved from the PDB
[37], the entry codes being presented in Table 1. Most of
the structures are crystallographic. Two NMR structures
are also used: the C-terminal domain of human centrin 2
in complex with the repeat sequence of human Sfi 1 and
the human BCL-XL in complex with the BAK peptide.
Multiple sequences alignment (Figure 1) shows low se-
quence identity for the most of the analyzed proteins
(shown in Table 2) both for the entire sequences and for
the binding areas. The binding areas included all residues
of the protein interacting with the alpha-helical peptide.
Chicken, human, E. coli and rat calmodulin have very
similar sequences (rat, chicken and human calmodulin are
100% identical; E coli has 98% identity with the others).
For BCL-XL and human ubiquitin carboxyl-terminal
hydrolase MDM2 only those fragments of sequences that
are present in the 3D structures are considered. There is a
high similarity only between the calmodulin, centrin 2 and
troponin C sequences.
Structure-based analysis
Figure 2 illustrates the complexes’ structures of six alpha-
helix binding proteins. In all shown complexes, bulky
Figure 3 3D structures of alpha-helix binding domains. (a)
Superposition of the alpha-helix binding regions of chicken
calmodulin (red, code entry 2O5G), HsCen2 (blue, code entry 2GGM),
scherffelia dubbia centrin (green, code entry 3KF9) and rabbit
troponin C (yellow, code entry 1A2X). (b) Structure of human BCL-XL
binding domain (code entry 1BXL). (c) Structure of human E3
ubiquitin-protein ligase MDM2 (code entry 1YCR) binding domain.
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hydrophobic residues of the bound peptide anchor into
the protein binding pocket. Following the sequence simi-
larities we superimposed the alpha-helix binding regions
structures of calmodulin, human centrin 2, scherffelia
dubia centrin and rabbit troponin C (Figure 3a). Strong
structural homology for binding regions is seen following
the sequence similarity of these proteins. Figure 3b and 3c
illustrate the binding pockets of BCL-XL and human E3
ubiquitin-protein ligase MDM2, respectively.
The interacting residues of the proteins and bound
peptides, identified with ContPro [29], are shown in
Figures 1 and 4 and Table 1. The results reveal that usually
hydrophobic residues such as TRP, LEU, ILE, PHE, VAL,
MET are involved in the interactions. The presence of hy-
drophobic residues suggests a favorable interaction with
terphenyl-like molecules anchoring in the hydrophobic
cavities. Most of the residues involved in the interactions
between the proteins and alpha-helices are hydrophobic
for both partners, as also observed in other studies [38].
We notice several key residues involved in the interaction
of the same protein with different peptide partners. For
example, in the case of calmodulin, PHE92, MET124,
PHE141, MET144 and MET145 are involved in most of
the peptides’ interactions. These residues can thus be
Figure 4 Illustration of the interacting residues (in sticks) of the protein (atom color type) and the bound peptide (red): (a) chicken
calmodulin and smMLCK (code entry 2O5G), (b) human centrin 2 and the centrin binding region of XPC (code entry 2GGM), (c) human BCL-XL
protein and BAK (code entry 1BXL), (d) human E3 ubiquitin- protein ligase MDM2 and p53 tumor transactivation domain (code entry 1YCR), (e)
rabbit cardiac troponin C and cardiac troponin I (code entry 1A2X).
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considered as key for the interaction with terphenyl and
its derivatives, or other alpha-helix mimetics. We noticed
the presence of MET residues in most of the alpha-helix
binding pockets analyzed here. In a recent study, MET
residues have not been identified to be a part of hot spot
amino acids, in particular in alpha-helix mediated protein
interfaces [39]. However, our analysis clearly indicates
their presence in positions that are key for the inter-
action with the alpha-helical partner. Furthermore, Ma
and Nussinov [40] have also concluded that the amino
acids TRP, MET, and PHE are important for protein-
protein interactions. They showed that TRP/MET/
PHE residues play roles in the dimerization of the
transcriptase (p51/p66) and in cell-fusion processes,
including the gp120-CD4 interaction and the gp41
six-helix bundle formation. They suggested that pola-
rizability of MET allows it to assume roles of both
hydrophobic and hydrophilic residues [40]. Further, its
larger flexibility compared to other hydrophobic resi-
dues may facilitate the plasticity of hydrophobic bind-
ing pockets allowing to accommodate different ligands
[27].
We used Fpocket [33] and CASTp [32] to calculate
geometrical and physicochemical characteristics of the
binding pockets taking into account the protein residues
interacting with the alpha-helical peptides. The overall
hydrophobic character of the binding pockets is again
clearly identified. Yet, some specificity is also observed,
several pockets show high hydrophobicity score but low
local hydrophobic density, or vice versa, demonstrating
that the hydrophobic patches are not always regularly
distributed in the binding pockets. For example, 1YCR
and 3KF9 have similar hydrophobicity scores but high
and low calculated hydrophobic density, respectively.
The differences of the hydrophobicity distribution are
illustrated in Figure 5.
The volumes of the detected pockets in the peptide-
binding regions computed with CASTp are given in
Table 3. The average volume of the sub-cavities present at
the PPI interfaces found by Fuller et al [41] was ~60 Å3.
Sonavane & Chakrabarti [42] found PPI pocket volumes
to be up to ~330 Å3. We found similar volumes to those
reported in Bourgeas et al. [43]. Taking into account the
various algorithms and different concepts for binding
pocket definition, such differences for the computed vol-
umes can be expected. Several small cavities are present in
the binding region (seen in Figure 2 and Figure 5), as it
has been previously observed for other targeted PPI inter-
faces [39]. For the proteins studied here, the presence of
several small hydrophobic cavities in the alpha-helix bind-
ing region seems to be a typical surface feature guiding
the anchoring of hydrophobic residues from the peptide
side. Such characteristics can also facilitate targeting PPI
mediated by alpha-helices by small molecules containing
hydrophobic anchors (as terphenyl or other mimetics).
Further, we decided to explore the roughness of the
alpha-helix binding sites. The methodology implemented
to calculate the fractal surface dimensions, used for the
roughness evaluation, is illustrated in Figure 6 for the
global surface roughness of chicken calmodulin. The
fractal global surface dimension and the fractal local sur-
face dimension for the binding site of chicken calmodu-
lin are calculated to be DS=2.238; ± 0.006 and DL= 2.616 ±
0.072, respectively. The global and local fractal dimensions
for the other proteins are given in Table 4. Our results
and other previously published data [44-47] suggest
that the global fractal dimension of protein surface is
Figure 5 Surface lipophilicity (shown in green) of alpha-helix
binding proteins computed using MOE. (a) Human E3 ubiquitin-
protein ligase MDM2 (PDB code 1YCR), (b) Scherffelia dubia centrin
(PDB code 3KF9).
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about 2. The local surface fractal dimensions for the
binding cavities are computed to be larger than the
global surface fractal dimensions for all studied pro-
teins. This reflects the higher roughness of the binding
site and its more complex shape and that can be consid-
ered as important for ligand binding. The most important
differences between DS and DL are obtained for human
calmodulin (2VAY), centrin (3KF9, 2K2I), BCL-XL
(1BXL), MDM2 (1YCR) and troponin C (1A2X). It has
been experimentally demonstrated that human calmodu-
lin [18], BCL-XL [19,20] and MDM2 [21,22] interact
with terphenyl or its derivatives. Recently, we suggested
Table 3 Geometrical and physicochemical characteristics of the identified pockets
Protein code PDB Volume (Å3) Hydrophobicity score Local hydrophobic density
Chicken calmodulin 312.0 68.86 43.00
2O5G
Human calmodulin 203.0 68.86 42.00
1ZUZ
Human calmodulin 219.8 59.62 40.00
2VAY
Human calmodulin 226.4 61.00 39.32
3DVE
E.coli calmodulin 317.9 56.63 40.15
1QTX
Rat calmodulin 310.6 56.62 43.78
2HQW
Human centrin 2 147.9 41.47 32.00
2GGM
Human centrin 2 210.9 39.93 35.08
2K2I
Scherffelia dubia centrin 221.5 58.19 31.00
3KF9
Human BCL-XL 321.5 36.91 42.04
1BXL
Human E3 ubiquitin-protein ligase MDM2 201.9 51.18 55.20
1YCR
Rabbit cardiac troponin C 213.1 63.07 39.15
1A2X
Figure 6 Double logarithmical plot of the surface area versus
probe radii for chicken calmodulin (PDB code 2O5G).
Table 4 Global (DS) and local (DL) surface fractal
dimensions of investigated proteins
Code PDB DS DL
2O5G 2.238 ± 0.006 2.616 ± 0.072
1ZUZ 2.181 ± 0.007 2.487 ± 0.058
2VAY 2.183 ± 0.006 2.757 ± 0.108
3DVE 2.217 ± 0.003 2.418 ± 0.040
1QTX 2.302 ± 0.002 2.494 ± 0.069
2HQW 2.172 ± 0.002 2.454 ± 0.082
2GGM 2.247 ± 0.004 2.373 ± 0.018
2K2I 2.167 ± 0.008 2.892 ± 0.124
3KF9 2.179 ± 0.006 2.892 ± 0.153
1BXL 2.230 ± 0.007 2.696 ± 0.225
1YCR 2.173 ± 0.014 2.708 ± 0.055
1A2X 2.177 ± 0.005 2.624 ± 0.032
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a possible binding of terphenyl 2, which mimics the rela-
tive positions of the side chains of residues TRP848,
LEU851, LEU855 of the XPC peptide, into human centrin
2 following our energetic and conformational flexibility
analysis performed for the alpha-helical peptide-binding
pocket of centrin 2 [27]. The DL value for the peptide-
binding site of troponin C shows rougher surface than the
entire protein, similarly to the above listed terphenyl-
binding proteins.
Taking into consideration the sequence and structural
homology of troponin C and calmodulin and other
physicochemical similarities of the binding sites as
discussed above, we decided to probe putative terphenyl
binding into troponin C. We performed docking of
terphenyl 2 into the peptide-binding sites of calmodulin
and troponin C using AutoDock. The best scored
docking poses are shown in Figure 7. The terphenyl ori-
entations in the best scored poses correspond to the
position of the bound alpha-helical peptides shown in
Figure 2. The predicted interaction energies of -7.98
and -8.18 kcal/mol for terphenyl binding in calmodulin
and troponin C, respectively, suggest favorable interac-
tions with the two proteins.
In the light of the results obtained here, it is now
interesting to discuss the physicochemical properties of
known PPI modulators, such as terphenyl. In a previous
work [10] we gathered a set of 66 PPI inhibitors among
which some terphenyl derivatives and other inhibitors
of alpha-helix mediated PPI were present. In that work
we demonstrated the more hydrophobic character of
these compounds but also their bigger size. Interes-
tingly, we also showed the importance of a critical num-
ber of aromatic bonds and some specific molecular
shapes (T-shaped, star-shaped, or L-shaped com-
pounds), among which some correspond to terphenyl
derivatives. The present work therefore confirms that
such genuine properties on the ligand side seem to be
cavity-driven, and that these small molecules must pos-
sess certain properties in order to efficiently modulate
an alpha-helix mediated PPI and to mimic the native
partner and its properties.
Conclusions
Modulating protein-protein interactions using small mole-
cules based on surface recognition has been a field of in-
creasing interest during the last decade. PPI interfaces are
very complex and need to be analyzed in order to be effi-
ciently targeted for drug discovery purposes. Designed
compounds must bind with high affinity and selectivity to
the target protein. The low sequence identity found be-
tween some of the analyzed proteins suggests that there
are no sequence requirements for the ability of proteins to
bind alpha-helical peptides and consequently small-
molecule mimetics.
From the structural point of view, all investigated
proteins show larger surface fractal dimensions for the
peptide-binding pockets than the entire protein sur-
face reflecting the higher complexity of the shape of
the binding sites. Also, the presence of several hydro-
phobic patches at the protein surface seems to be an
important property related to the ability of the protein
to bind alpha-helical peptides and mimetics. Further-
more, we showed that hydrophobicity is not uniformly
distributed across different alpha-helix binding pockets
and that its distribution can be used to identify hydro-
phobic hot spots.
Many similarities between the binding sites studied
here are observed and terphenyl or its derivatives bind-
ing to various alpha-helix binding proteins can be sug-
gested. However, targeting various PPI complexes by
similar small molecules can rise selectivity problems in
the context of drug discovery or chemical biology
Figure 7 Best scored docking poses of terphenyl. The poses
after docking-scoring with AutoDock are shown in cyan. (a) chicken
calmodulin, code entry 2O5G, (b) rabbit cardiac troponin C, code
entry 1A2X.
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projects. Thus, the specificities found here for different
binding sites, e.g. key residues, roughness and local
hydrophobic density, can be further exploited to
optimize terphenyl-like ligands in order to improve
their selectivity.
Abbreviations
PPI: Protein-Protein interactions; smMLCK: smooth muscle myosin light chain
kinase; CaM: Calmodulin; HsCen2: Human centrin 2; PDE: 3'-5'-cyclic
nucleotide phosphodiesterase; XPC: Xeroderma pigmentosum group C.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AI carried out the sequence alignment and binding pockets analysis. DC
carried out the fractal calculations. AI and DC drafted the manuscript. VM
carried out the volume calculations and docking analysis. OS participated in
the protein-protein interface analysis and discussion writing. MAM designed
and coordinated the study. All authors participated in manuscript writing
and approved the final manuscript.
Acknowledgments
The financial support from the West University of Timisoara, the Inserm
institute and the University Paris Diderot is greatly appreciated.
Author details
1Department of Biology and Chemistry, West University of Timisoara, 16
Pestalozzi, Timisoara 300115, Romania. 2Advanced Environmental Researches
Laboratory, 4 Oituz, Timisoara 300086, Romania. 3Teacher Training
Department, West University of Timisoara, 4 Blvd. V. ParvanTimisoara 300223,
Romania. 4Université Paris Diderot, Sorbonne Paris Cité, Molécules
Thérapeutiques in silico, Inserm UMR-S 973, 35 rue Helene Brion, Paris 75013,
France. 5INSERM, U973, Paris F-75205, France.
Received: 23 January 2013 Accepted: 11 June 2013
Published: 14 June 2013
References
1. Hunter T, Maniatis T, Califano A, Honig B, Zhang QC, Petrey D, Deng L,
Qiang L, Shi Y, Thu CA, Bisikirska B, Lefebvre C, Accili D: Structure-based
prediction of protein-protein interactions on a genome-wide scale.
Nature 2012, 490:556–660.
2. Stumpf MP, Thorne T, de Silva E, Stewart R, An HJ, Lappe M, Wiuf C:
Estimating the size of the human interactome. Proc Natl Acad Sci USA
2008, 105:6959–6964.
3. Stockwell BR: Exploring biology with small organic molecules. Nature
2004, 432:846–854.
4. Wilson CG, Arkin MR: Small-molecule inhibitors of IL-2/IL-2R: Lessons
learned and applied. Curr Top Microbiol Immunol 2011, 348:25–29.
5. Villoutreix BO, Bastard K, Sperandio O, Fahraeus R, Poyet JL, Calvo F, Deprez
B, Miteva MA: In silico-in vitro screening of protein-protein interactions:
towards the next generation of therapeutics. Curr Pharm Biotechnol 2008,
9:103–122.
6. Fry DC: Protein-protein interactions as targets for small molecule drug
discovery. Biopolymers 2006, 84:535–552.
7. Gautier B, Miteva MA, Goncalves V, Huguenot F, Coric P, Bouaziz S, Seijo B,
Gaucher JF, Broutin I, Garbay C, Lesnard A, Rault S, Inguimbert N, Villoutreix
BO, Vidal M: Targeting the proangiogenic VEGF-VEGFR protein-protein
interface with drug-like compounds by in silico and in vitro screening.
Chem Biol 2011, 18(12):1631–1639.
8. Villoutreix BO, Laconde G, Lagorce D, Martineau P, Miteva MA, Dariavach
P: Tyrosine kinase syk non-enzymatic inhibitors and potential
anti-allergic drug-like compounds discovered by virtual and in vitro
screening. PLoS One 2011, 6(6):e21117.
9. Wells JA, McClendon CL: Reaching for high-hanging fruit in drug
discovery at protein-protein interfaces. Nature 2007, 450:1001–1009.
10. Sperandio O, Reynes CH, Camproux AC, Villoutreix BO: Rationalizing the
chemical space of protein-protein interaction inhibitors. Drug Discov
Today 2010, 15:220–229.
11. Morelli X, Bourgeas R, Roche P: Chemical and structural lessons from
recent successes in protein-protein interaction inhibition (2P2I). Curr Opin
Chem Biol 2011, 15:475–481.
12. Tripathi A, Kellogg GE: A Novel and Efficient Tool for Locating and
Characterizing Protein Cavities and Binding Sites. Proteins 2010,
78(4):825–842.
13. Grosdidier S, Fernández-Recio J: Protein-protein Docking and Hot-spot
Prediction for Drug Discovery. Curr Pharm Des 2012, 18(30):4607–4618.
14. Andersson CD, Chen BY, Linusson A: Mapping of ligand-binding cavities in
proteins. Proteins 2010, 78(6):1408–1422.
15. Koes D, Khoury K, Huang Y, Wang W, Bista M, Popowicz GM, Wolf S, Holak
TA, Domling A, Camacho CJ: Enabling Large-Scale Design, Synthesis and
Validation of Small Molecule Protein-Protein Antagonists. PLoS One 2012,
7(3):e32839.
16. Petsko GA, Ringe D: Protein structure and function. London: New Science
Press Ltd; 2004.
17. Bullock BN, Jochim AL, Arora PS: Assessing helical protein interfaces
for inhibitor Design. J Am Chem Soc 2011, 133(36):14220–14223.
18. Orner BP, Ernst JT, Hamilton AD: Towards Proteomimetics: Terphenyl
Derivatives as Structural and Functional Mimics of Extended Regions of
an a-Helix. J Am Chem Soc 2001, 123(22):5382–5383.
19. Kutzki O, Park HS, Ernst JT, Orner BP, Yin H, Hamilton AD: Development of a
Potent Bcl-xL Antagonist Based on r-Helix Mimicry. J Am Chem Soc 2002,
124(40):11838–11839.
20. Yin H, Lee GI, Sedey KA, Kutzki O, Park HS, Orner BP, Ernst JT, Wang HG,
Sebti SM, Hamilton AD: Terphenyl-Based Bak BH3 alpha-helical
proteomimetics as low-molecular-weight antagonists of Bcl-xL. J Am
Chem Soc 2005, 127(29):10191–10196.
21. Yin H, Lee G, Park HS, Payne GA, Rodriguez JM, Sebti SM, Hamilton AD:
Terphenyl-Based Helical Mimetics That Disrupt the p53/HDM2
Interaction. Angew Chem 2005, 117(18):2764–2767.
22. Chen L, Yin H, Farooqi B, Sebti S, Hamilton AD, Chen J: p53 alpha-Helix
mimetics antagonize p53/MDM2 interaction and activate p53. Mol Canc
Ther 2005, 4(6):1019–1025.
23. Che Y, Brooks BR, Marshall GR: Protein recognition motifs: design of
peptidomimetics of helix surfaces. Biopolymers 2007, 86(4):288–297.
24. Becerril J, Rodriguez JM, Wyrembak PN, Hamilton AD: Inhibition of
protein-protein interaction by peptide mimics. In Protein Surface
Recognition: Approaches for Drug Discovery. Edited by Giralt E, Peczuh M,
Salvatella X. London: John Willey&Sons; 2011.
25. Fairlie DP, West ML, Wong AK: Towards protein surface mimetics. Curr Med
Chem 1998, 5(1):29–62.
26. Maity P, König B: Synthesis and structure of 1,4-dipiperazino benzenes:
chiral terphenyl-type peptide helix mimetics. Org Lett 2008,
10(7):1473–1476.
27. Isvoran A, Badel A, Craescu CT, Miron S, Miteva MA: Exploring NMR
ensembles of calcium binding proteins: Perspectives to design inhibitors
of protein-protein interactions. BMC Struct Biol 2011, 11:24.
28. Thompson JD, Higgins DG, Gibson TJ: CLUSTAL W: lmproving the
sensitivity of progressive multiple sequence alignment through
sequence weighting, position specific gap penalties and weight matrix
choice. Nucleic Acids Res 1994, 22:4673–4680.
29. Firoz A, Malik A, Afzal O, Jha V: ContPro: A web tool for calculating amino
acid contact distances in protein from 3D –structure at different
distance threshold. Bioinformation 2010, 5(2):55–57.
30. Lewis M, Rees DC: Fractal surfaces of proteins. Science 1985,
230:1163–1165.
31. Fraczkiewicz R, Braun W: Exact and efficient analytical calculation of
accesible surface areas and their gradients for macromolecules. J Compl
Chem 1998, 19:319–333.
32. Dundas J, Ouyang Z, Tseng J, Binkowski A, Turpaz Y, Liang J: CASTp:
computed atlas of surface topography of proteins with structural and
topographical mapping of functionally annotated resiudes. Nucleic Acid
Res 2006, 34:W116–W118.
33. Guilleoux VL, Schmidtke P, Tuffery P: Fpocket; An open source platform for
ligand binding pocket detection. BMC Bioinforma 2009, 10:168.
34. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson
AJ: AutoDock4 and AutoDockTools4: Automated docking with selective
receptor flexibility. J Comput Chem 2009, 30(16):2785–2791.
35. DeLano WL: The PyMol molecular graphics system. San Carlos: DeLano
Scientific; 2002.
Isvoran et al. BMC Pharmacology and Toxicology 2013, 14:31 Page 10 of 11
http://www.biomedcentral.com/2050-6511/14/31
36. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC,
Ferrin TE: UCSF Chimera--a visualization system for exploratory research
and analysis. J Comput Chem 2004, 25(13):1605–1612.
37. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H,
Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res 2000,
28:235–242.
38. Moreira IS, Fernandes PA, Ramos MJ: Hot spots—A review of the
protein–protein interface determinant amino-acid residues. Proteins
Struct Funct Bioinform 2007, 68(4):803–812.
39. Brooke N, Bullock A, Paramjit SA: Assessing Helical Protein Interfaces for
Inhibitor Design. J Am Chem Soc 2011, 133(36):14220–14223.
40. Ma B, Nussinov R: Trp/Met/Phe Hot Spots in Protein-Protein Interactions:
Potential Targets in Drug Design. Curr Top Med Chem 2007, 7:999–1005.
41. Fuller JC, Burgoyne NJ, Jackson RM: Predicting druggable binding sites at
the protein–protein interface. Drug Discov Today 2009, 14(3–4):155–161.
42. Sonavane S, Chakrabarti P: Cavities and Atomic Packing in Protein
Structures and Interfaces. PLoS Comput Biol 2008, 4:e100001188.
43. Bourgeas R, Basse MJ, Morelli X, Roche P: Atomic Analysis of Protein-
Protein Interfaces with Known Inhibitors: The 2P2I Database. PLoS
One 2010, 3:e9598.
44. Goetze T, Brickmann J: Self similarity of protein surfaces. Biophys J 1992,
61:109–118.
45. Pettit FK, Bowie JU: Protein surface roughness and small molecular
binding sites. J Mol Biol 1999, 285(4):1377–1382.
46. Stawiski EW, Baucom AE, Lohr SC, Gregoret LM: Predicting protein function
from structure: Unique structural features of proteases. Proc Natl Acad Sci
2000, 97:3954–3958.
47. Stawiski EW, Mandel-Goutfreund Y, Lowenthal AC, Gregoret LM: Progress in
predicting protein structure from sequence: unique features of O-
glycosidases. Pacific Symp Biocomput 2002, 7:637–648.
doi:10.1186/2050-6511-14-31
Cite this article as: Isvoran et al.: Computational analysis of protein-
protein interfaces involving an alpha helix: insights for terphenyl–like
molecules binding. BMC Pharmacology and Toxicology 2013 14:31.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Isvoran et al. BMC Pharmacology and Toxicology 2013, 14:31 Page 11 of 11
http://www.biomedcentral.com/2050-6511/14/31
